Skip to main content

Table 2 Occurrence of contrast nephropathy (several definitions) according to the group of inclusion (placebo or n-acetylcysteine)

From: N-acetylcysteine does not prevent contrast nephropathy in patients with renal impairment undergoing emergency CT: a randomized study

Event Placebo NAC P-value
(n = 58) (n = 52)
25% increase of creatinine or cystatin C 13 (22.4%) 14 (26.9%) 0.66
25% increase creatinine 10 (17.2%) 8 (15.4%) 0.99
25% increase cystatin C 9 (15.5%) 9 (17.3%) 0.99
AKIN stage 1 11 (19.0%) 13 (25.0%) 0.49
AKIN all stages 12 (20.7%) 13 (25.0%) 0.65